EU Extends Pilot Of New Drug Safety Reporting System
Executive Summary
Testing of the enhanced EU drug safety reporting system, EudraVigilance, is to be extended beyond February in an effort to gain more information on how stakeholders are finding the new requirements.
You may also be interested in...
EU Makes ISO Format Mandatory For Side-Effect Reporting From June 2022
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
EU Safety Signal Detection Pilot Extended Again
The pilot phase of a European project on new safety signal notification requirements has been extended for a second time following inconclusive results.
EMA Outlines Regulatory Expectations On Use Of Patient Registries
Building on its ongoing patient registry initiative, the European Medicines Agency has issued recommendations on the methodological and operational aspects of the use of patient disease registries and registry studies for regulatory purposes.